Call for Abstract

sponsored by Proteona

Single Cell Multi-Omics Grant for Multiple Myeloma

Awards up to $50,000 worth of single cell proteogenomic analysis, sequencing, and bioinformatics services for translational oncology projects.

About the grant call

Multiple myeloma (MM) is an incurable plasma cell malignancy characterised by heterogeneous and rapidly evolving tumors that lead to frequent relapses. Following each relapse, MM therapy tends to get more expensive and have shorter progression-free survival time. Such a cycle of higher costs and lower efficacy is not sustainable for patients nor payors and must be disrupted.

At Proteona, we believe that multiple myeloma represents an excellent use cases for single cell multi-omic analysis, as the heterogeneity and rapid evolution of the tumors has made treatment so difficult. Our multi-omic single cell analysis technologies, combined with our state-of-the-art data analysis tools, provide a powerful platform to understand and better treat the disease. Enhanced Single Cell Analysis with Protein Expression and RNA Sequencing (ESCAPE™ RNA-Seq) is an innovative platform for obtaining protein expression, gene expression, and mutation information from the same single cells. By further adding sample-specific clinical information, it is possible to analyse clone-specific drug response, resistance mechanism, and even predict treatment outcome at the greatest precision ever.

Proteona is providing a $50,000 grant for its single cell multi-omic services and data analysis tools to the most innovative clinical research projects in multiple myeloma or other hematological malignancies. Simply submit a 300 word or less abstract to share with us how you will use the ESCAPE™ RNA-Seq platform to analyse your clinical samples and how you will make use of the data.

Winner, 2019 Proteona Grant Call

Dr Cesar Rodriguez Valdes

"We are excited about combining Proteona's single-cell proteogenomic analysis with our patient-derived organoid screening platform. Our ambition is to develop a predictive, validated test that will facilitate clinical decision-making and improve the outcome of multiple myeloma treatment. This grant will help us to move closer to that goal.”

Cesar Rodriguez Valdes
Assistant Professor, Hematologist
Wake Forest School of Medicine

Read about the previous winners of Proteona Grant Call

For any additional information, email


  • All proposals will be carefully reviewed by a team of scientists from Proteona. Short-listed applicants will be notified by email for further assessment. Winners will be selected based on the novelty and anticipated scientific and clinical impact of the research.
  • Entries are welcome from all fields of oncology including, but not limited to: cell therapy, tumor and tumor microenvironment analysis, and drug screening including the use of tumor organoids.
  • We welcome entries from all academic researchers, regardless of position or title.
  • Additional awards may also be given at Proteona’s discretion. Only first-time users of ESCAPE™ RNA-Seq technology are eligible for the Challenge.

Read the full terms and conditions here

Read our privacy policy here here

Apply now

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).